|
US5591855A
(en)
|
1994-10-14 |
1997-01-07 |
Cephalon, Inc. |
Fused pyrrolocarbazoles
|
|
US5628984A
(en)
|
1995-07-31 |
1997-05-13 |
University Of North Carolina At Chapel Hill |
Method of detecting lung disease
|
|
WO1998033798A2
(en)
|
1997-02-05 |
1998-08-06 |
Warner Lambert Company |
Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
|
|
GB9718913D0
(en)
|
1997-09-05 |
1997-11-12 |
Glaxo Group Ltd |
Substituted oxindole derivatives
|
|
US20040006074A1
(en)
|
1998-04-28 |
2004-01-08 |
The Government Of The United States Of America |
Cyclin dependent kinase (CDK)4 inhibitors and their use for treating cancer
|
|
JP4555476B2
(ja)
|
1998-06-16 |
2010-09-29 |
ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ， アズ レプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
縮合アゼピノン型サイクリン依存性キナーゼ阻害物質
|
|
IL144294A0
(en)
|
1999-01-29 |
2002-05-23 |
Univ Illinois |
P53 inhibitors and therapeutic use of the same
|
|
CA2380389A1
(en)
|
1999-07-26 |
2001-02-01 |
Banyu Pharmaceutical Co., Ltd. |
Biarylurea derivatives
|
|
US6387900B1
(en)
|
1999-08-12 |
2002-05-14 |
Pharmacia & Upjohn S.P.A. |
3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
|
|
US6291504B1
(en)
|
1999-10-20 |
2001-09-18 |
Dupont Pharmaceuticals Company |
Acylsemicarbazides and their uses
|
|
EP1242420A2
(en)
|
1999-12-16 |
2002-09-25 |
Eli Lilly And Company |
Agents and methods for the treatment of proliferative diseases
|
|
US7053070B2
(en)
|
2000-01-25 |
2006-05-30 |
Warner-Lambert Company |
Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
|
|
ATE423120T1
(de)
|
2000-06-26 |
2009-03-15 |
Pfizer Prod Inc |
Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe
|
|
AU2001292579A1
(en)
|
2000-09-29 |
2002-04-15 |
Eli Lilly And Company |
Methods and compounds for treating proliferative diseases
|
|
WO2002044174A2
(en)
|
2000-12-01 |
2002-06-06 |
Bristol-Myers Squibb Pharma Company |
3-(2,4-dimethylthiazol-5-yl) indeno[1,2-c]pyrazol-4-one derivatives as cdk inhibitors
|
|
AU2002305942B2
(en)
|
2001-02-28 |
2006-10-26 |
Onconova Therapeutics, Inc. |
Method for protecting cells and tissues from ionizing radiation toxicity with Alpha, Beta unsaturated aryl sulfones
|
|
KR100863624B1
(ko)
*
|
2001-05-11 |
2008-10-15 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
Ｃｄ26을 발현하는 세포와 연관된 질환의 치료제로사용되는 항-ｃｄ26 단클론항체
|
|
MXPA04005939A
(es)
|
2002-01-22 |
2005-01-25 |
Warner Lambert Co |
2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
|
|
WO2003093469A2
(en)
|
2002-05-01 |
2003-11-13 |
Chromos Molecular Systems, Inc. |
Methods for delivering nucleic acid molecules into cells and assessment thereof
|
|
MXPA05007503A
(es)
|
2003-01-17 |
2005-09-21 |
Warner Lambert Co |
Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
|
|
BR122019010200B8
(pt)
|
2003-05-22 |
2021-07-27 |
Nerviano Medical Science S R L |
compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
|
|
AU2004255934B2
(en)
|
2003-07-11 |
2010-02-25 |
Warner-Lambert Company Llc |
Isethionate salt of a selective CDK4 inhibitor
|
|
ES2297502T3
(es)
|
2003-10-23 |
2008-05-01 |
F. Hoffmann-La Roche Ag |
Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos.
|
|
GB0327380D0
(en)
|
2003-11-25 |
2003-12-31 |
Cyclacel Ltd |
Method
|
|
WO2005094830A1
(en)
|
2004-03-30 |
2005-10-13 |
Pfizer Products Inc. |
Combinations of signal transduction inhibitors
|
|
WO2005100999A2
(en)
|
2004-04-08 |
2005-10-27 |
Cornell Research Foundation, Inc. |
Functional immunohistochemical cell cycle analysis as a prognostic indicator for cancer
|
|
ITMI20040874A1
(it)
|
2004-04-30 |
2004-07-30 |
Ist Naz Stud Cura Dei Tumori |
Derivati indolici ed azaindolici con azione antitumorale
|
|
EP1846408B1
(en)
|
2005-01-14 |
2013-03-20 |
Janssen Pharmaceutica NV |
5-membered annelated heterocyclic pyrimidines as kinase inhibitors
|
|
EP1845975A1
(en)
|
2005-01-21 |
2007-10-24 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors and further antitumor agents
|
|
EP2354140A1
(en)
|
2005-05-20 |
2011-08-10 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
|
EP1779848A1
(en)
|
2005-10-28 |
2007-05-02 |
Nikem Research S.R.L. |
V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
|
|
DE602006010433D1
(de)
|
2005-12-09 |
2009-12-24 |
Hoffmann La Roche |
Für die behandlung von obesitas geeignete tricyclische amidderivate
|
|
AU2006331765A1
(en)
|
2005-12-22 |
2007-07-05 |
Wyeth |
Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3(2H)-isoquinolones and use thereof as kinase inhibitor
|
|
US20090098137A1
(en)
|
2006-04-05 |
2009-04-16 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
US20070270362A1
(en)
|
2006-05-18 |
2007-11-22 |
The University Of Washington |
Methods and compositions for prevention or treatment of inflammatory-related diseases and disorders
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
EP2109450A2
(en)
|
2006-12-14 |
2009-10-21 |
Panacea Pharmaceuticals, Inc. |
Methods of neuroprotection by cyclin-dependent kinase inhibition
|
|
CN101568529A
(zh)
|
2006-12-22 |
2009-10-28 |
诺瓦提斯公司 |
作为cdk抑制剂、用于治疗癌症、炎症和病毒感染的杂芳基-杂芳基化合物
|
|
CA2690748A1
(en)
|
2007-06-25 |
2008-12-31 |
Neurogen Corporation |
Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
|
|
WO2009061345A2
(en)
|
2007-11-07 |
2009-05-14 |
Cornell Research Foundation, Inc. |
Targeting cdk4 and cdk6 in cancer therapy
|
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
|
EP2320903B1
(en)
|
2008-07-29 |
2017-01-18 |
Nerviano Medical Sciences S.r.l. |
THERAPEUTIC COMBINATION COMPRISING A CDKs INHIBITOR AND AN ANTINEOPLASTIC AGENT
|
|
ES2522346T3
(es)
|
2008-08-22 |
2014-11-14 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de CDK
|
|
CN102231983A
(zh)
|
2008-10-01 |
2011-11-02 |
北卡罗来纳大学查珀尔希尔分校 |
使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
|
|
JP2012504646A
(ja)
|
2008-10-01 |
2012-02-23 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
|
|
PA8852901A1
(es)
|
2008-12-22 |
2010-07-27 |
Lilly Co Eli |
Inhibidores de proteina cinasa
|
|
JP2012526850A
(ja)
|
2009-05-13 |
2012-11-01 |
ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル |
サイクリン依存性キナーゼ阻害剤及びその用法
|
|
US9040519B2
(en)
|
2010-02-18 |
2015-05-26 |
Medivation Technologies, Inc. |
Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
|
|
UY33227A
(es)
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
|
|
UY33226A
(es)
*
|
2010-02-19 |
2011-09-30 |
Novartis Ag |
Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
|
|
MX338327B
(es)
|
2010-10-25 |
2016-04-12 |
G1 Therapeutics Inc |
Inhibidores de cdk.
|
|
US8691830B2
(en)
|
2010-10-25 |
2014-04-08 |
G1 Therapeutics, Inc. |
CDK inhibitors
|
|
WO2012061477A1
(en)
|
2010-11-02 |
2012-05-10 |
Promega Corporation |
Coelenterazine derivatives and methods of using same
|
|
WO2012068381A2
(en)
|
2010-11-17 |
2012-05-24 |
The University Of North Carolina At Chapel Hill |
Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
|
|
DK2655375T3
(en)
|
2010-12-23 |
2015-03-09 |
Sanofi Sa |
PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
|
|
EP2937349B1
(en)
*
|
2011-03-23 |
2016-12-28 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
|
EP2726074B1
(en)
|
2011-07-01 |
2018-04-04 |
Novartis AG |
Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
|
|
CA2868966C
(en)
|
2012-03-29 |
2021-01-26 |
Francis Xavier Tavares |
Lactam kinase inhibitors
|
|
CA2870019C
(en)
|
2012-04-26 |
2020-08-18 |
Francis Xavier Tavares |
Synthesis of lactams
|
|
US9241941B2
(en)
|
2012-09-20 |
2016-01-26 |
Memorial Sloan-Kettering Cancer Center |
Methods for treatment of lymphomas with mutations in cell cycle genes
|
|
ME03557B
(me)
|
2013-03-15 |
2020-07-20 |
G1 Therapeutics Inc |
Privremena zaštiтa normalnih ćelija током hemoterapije
|
|
CA2906157C
(en)
|
2013-03-15 |
2022-05-17 |
G1 Therapeutics, Inc. |
Highly active anti-neoplastic and anti-proliferative agents
|
|
US20140274896A1
(en)
|
2013-03-15 |
2014-09-18 |
G1 Therapeutics, Inc. |
Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
|
|
EP2983670A4
(en)
|
2013-04-08 |
2017-03-08 |
Pharmacyclics LLC |
Ibrutinib combination therapy
|
|
US20160257688A1
(en)
|
2013-10-24 |
2016-09-08 |
Francis Xavier Tavares |
Process for Synthesis of Lactams
|
|
WO2015084892A1
(en)
|
2013-12-02 |
2015-06-11 |
Cornell University |
Methods for treating b cell proliferative disorders
|
|
WO2015161288A1
(en)
|
2014-04-17 |
2015-10-22 |
G1 Therapeutics, Inc. |
Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
|
|
WO2016040848A1
(en)
|
2014-09-12 |
2016-03-17 |
G1 Therapeutics, Inc. |
Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
|
|
EP3191098A4
(en)
|
2014-09-12 |
2018-04-25 |
G1 Therapeutics, Inc. |
Combinations and dosing regimes to treat rb-positive tumors
|
|
WO2016126889A1
(en)
|
2015-02-03 |
2016-08-11 |
G1 Therapeutics, Inc. |
Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
|